英夫利昔单抗和来氟米特成功治疗儿童难治性局限性硬皮病的病例报告
A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide.
作者信息
Ferguson Ian D, Weiser Peter, Torok Kathryn S
机构信息
Department of Pediatrics, Division of Rheumatology, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.
Department of Pediatrics, Division of Rheumatology, Children's of Alabama, University of Alabama at Birmingham, 1600 7th Ave S, CPP North M210, Birmingham, AL, 35233, USA.
出版信息
Open Rheumatol J. 2015 Jun 26;9:30-5. doi: 10.2174/18743129014090100030. eCollection 2015.
Herein we report successful treatment of an adolescent Caucasian female with severe progressive localized scleroderma (mixed subtype, including generalized morphea and linear scleroderma of the trunk/limb) using infliximab and leflunomide. The patient demonstrated improvement after the first 9 months of therapy based on her clinical examination, objective measures, and patient and parent global assessments. Infliximab is a potential treatment option for pediatric localized scleroderma patients who have progression of disease or who are unable to tolerate the side effect profile of more standard systemic therapy. Larger longitudinal studies or case series are needed to confirm and further investigate infliximab's role in localized scleroderma.
在此，我们报告了一例患有严重进行性局限性硬皮病（混合亚型，包括泛发性硬斑病和躯干/肢体线状硬皮病）的青春期白种女性患者，使用英夫利昔单抗和来氟米特治疗成功。根据临床检查、客观测量以及患者和家长的整体评估，该患者在治疗的前9个月后病情有所改善。对于患有疾病进展或无法耐受更标准全身治疗副作用的儿科局限性硬皮病患者，英夫利昔单抗是一种潜在的治疗选择。需要更大规模的纵向研究或病例系列来证实并进一步研究英夫利昔单抗在局限性硬皮病中的作用。
Zotero 插件